Between Seroquel, Nexium and Crestor, AstraZeneca investors may have felt over the past few years that the extended fall off the patent cliff would never stop smarting. But the company promises things will turn around if they’ll just hang on.
Say what you want about AstraZeneca’s castoff strategy, but it helped drive another earnings beat for the lacking-in-sales drugmaker to kick off the year.
In 2013, it looked as if AstraZeneca and Ranbaxy could face billions in damages in a lawsuit alleging they struck an illegal deal to block a Nexium generic. Now, that cloud has lifted.
